-
Marchés
-
Actions
Sustainable finance2025 Euronext ESG Trends ReportLire la suiteA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLire la suiteInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fonds
-
Obligations
European Defence BondsGroupe BPCE lists the first bondLire la suiteFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Produits Structurés
-
Dérivés
Where European Government Bonds Meet the FutureFixed Income derivativesLire la suiteTrade mini bond futures on main European government bonds
-
Marchandises
- Vue d'ensemble
- Vue d'ensemble
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Règlement livraison
- Spécifications et dispositions
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLire la suiteEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLire la suiteJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 24 Nov 2025 16:40 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 24 Nov 2025 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly Report Q3 2025 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 13 Nov 2025 08:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Invitation to Q3 2025 Financial Results Presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 05 Nov 2025 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection Method from Two Clinical Trials at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 04 Nov 2025 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. Patent for the Neoantigen Selection Method for VB10.NEO, Nykode’s Individualized Neoantigen Therapy | 20103010 Biotechnology | Non-regulatory press releases |
| 14 Oct 2025 08:17 CEST |
NYKODE THERAPEUTICS ASA | Disclosure of Large Shareholding - Nykode Therapeutics ASA | 20103010 Biotechnology | Major shareholding notifications |
| 10 Oct 2025 17:44 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Grant of Share Options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 10 Oct 2025 14:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 10 Oct 2025 12:36 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 09 Oct 2025 20:27 CEST |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Aug 2025 07:01 CEST |
NYKODE THERAPEUTICS ASA | Nykode Announces Updated Strategy to Increase Value for Patients and Shareholders, Prioritizing VB10.16 as the Lead Value Driver | 20103010 Biotechnology | Inside information |
| 27 Aug 2025 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q2 2025 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 20 Aug 2025 08:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Invitation to Q2 2025 Financial Results Presentation and Strategy Update | 20103010 Biotechnology | Non-regulatory press releases |
| 09 Jul 2025 18:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Grant of Share Options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 04 Jul 2025 16:41 CEST |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2025 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q1 2025 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 27 May 2025 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Ex-dividend NOK 1.00 today | 20103010 Biotechnology | Ex Date |
| 26 May 2025 16:51 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q1 2025 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 26 May 2025 11:25 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 May 2025 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Highlights New Data in Two Poster Presentations at the 2025 ASCO Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 05 May 2025 08:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Apr 2025 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Annual Report 2024 | 20103010 Biotechnology | Annual financial and audit Reports |
| 28 Apr 2025 19:17 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Key information relating to proposed cash dividend | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Apr 2025 15:50 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Minutes of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Apr 2025 07:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode announces that Michael Engsig, CEO; Agnete Fredriksen, CSO & Co-founder; and Harald Gurvin, CFO; have withdrawn their recent resignations and continue with Nykode; proposal of new Board members; potential dividend of NOK 1.00 per share | 20103010 Biotechnology | Inside information |
| 11 Apr 2025 18:59 CEST |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Apr 2025 09:40 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Mar 2025 16:56 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 27 Mar 2025 14:15 CET |
NYKODE THERAPEUTICS ASA | OSLO BØRS – TRADING RESUMPTION | 20103010 Biotechnology | Trading halts |
| 27 Mar 2025 13:33 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – resignation of Chair of the Board, Board Members, Chief Executive Officer, Chief Scientific Officer and Chief Financial Officer | 20103010 Biotechnology | Inside information |
| 27 Mar 2025 13:30 CET |
NYKODE THERAPEUTICS ASA | OSLO BØRS - TRADING SUSPENSION | 20103010 Biotechnology | Trading halts |
| 27 Feb 2025 20:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform’s Ability to Modulate Multiple Key Immune Components in Autoimmune Disease | 20103010 Biotechnology | Non-regulatory press releases |
| 26 Feb 2025 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q4 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 14 Feb 2025 16:05 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q4 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Jan 2025 10:50 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Publication of Phase 2 VB-C-02 Data Confirming Prolonged Benefit and Definitive Vaccination Effects | 20103010 Biotechnology | Non-regulatory press releases |
| 30 Dec 2024 19:47 CET |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Dec 2024 13:35 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Streamlining Board of Directors | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Dec 2024 14:19 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory Notification of Trade | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 04 Dec 2024 19:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Presents New Data on Individualized Cancer Immunotherapy at the Personalized Cancer Vaccines Summit | 20103010 Biotechnology | Non-regulatory press releases |
| 27 Nov 2024 00:05 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q3 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 20 Nov 2024 18:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q3 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Nov 2024 15:18 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Nov 2024 15:10 CET |
NYKODE THERAPEUTICS ASA | Disclosure of large shareholding in Nykode Therapeutics ASA | 20103010 Biotechnology | Major shareholding notifications |
| 08 Nov 2024 00:15 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Webcast Invitation | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2024 23:25 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Regain Control of VB10.NEO Program | 20103010 Biotechnology | Inside information |
| 06 Nov 2024 17:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe | 20103010 Biotechnology | Non-regulatory press releases |
| 27 Sep 2024 08:11 CEST |
NYKODE THERAPEUTICS ASA | Major shareholding notification | 20103010 Biotechnology | Major shareholding notifications |
| 21 Aug 2024 16:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Aug 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q2 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 21 Aug 2024 06:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer | 20103010 Biotechnology | Inside information |